Brief: Checkpoint Therapeutics Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab In Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics

16/06/2022 12:35

June 16 (Reuters) - Checkpoint Therapeutics Inc  CKPT.O :
    * CHECKPOINT THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS
FROM
REGISTRATION-ENABLING TRIAL OF COSIBELIMAB IN LOCALLY ADVANCED
CUTANEOUS SQUAMOUS CELL CARCINOMA
    * CHECKPOINT THERAPEUTICS INC - OBJECTIVE RESPONSE RATE OF
54.8%
IN PATIENTS WITH LOCALLY ADVANCED CSCC, A POTENTIAL 2(ND)
INDICATION FOR COSIBELIMAB
    * CHECKPOINT THERAPEUTICS INC - PREVIOUSLY MET PRIMARY
ENDPOINT IN
PATIENTS WITH METASTATIC CSCC; BLA SUBMISSION ON TRACK FOR LATER
THIS YEAR
    * CHECKPOINT THERAPEUTICS INC - TO CONTINUE DISCUSSIONS WITH
FDA
ON POTENTIAL ADDITION OF LOCALLY ADVANCED INDICATION TO ITS
PLANNED BLA SUBMISSION

Source text for Eikon:  ID:nGNX8C6Pnh 
Further company coverage:  CKPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))